TRT For CDL Drivers And DOT Physicals

For commercial drivers, TRT for CDL drivers and DOT physicals raises a fair question: can you hold a valid medical card while on testosterone? Often yes, provided the treatment is properly prescribed, documented, and the driver meets the physical qualification standards. Testosterone for diagnosed hypogonadism does not automatically disqualify a driver, and testosterone is not part of the federal DOT drug test. What matters is that the treatment is legitimate, documented, and well managed.

That last point is where a driver's medical team does the real work. Direct-pay hormone care has made testosterone treatment easier to access, and this guide explains how medically supervised testosterone intersects with the federal medical exam: what examiners check, what the drug screen does and does not include, and how blood pressure and hematocrit affect certification.

Does TRT disqualify a CDL driver from a DOT physical?

No, testosterone therapy does not disqualify a driver on its own. The Federal Motor Carrier Safety Administration (FMCSA) does not name testosterone replacement therapy or hypogonadism as disqualifying conditions, and a legally prescribed medication is permitted when the treating provider confirms it will not interfere with safe driving (49 CFR 391.41).

A DOT physical is the federally required medical exam that determines whether a commercial driver is fit to operate a commercial motor vehicle. For a driver on testosterone, the exam does not measure hormone levels. It evaluates overall fitness, including vision, hearing, blood pressure, and any medication that could affect safe operation.

So the concern for most drivers is not the diagnosis of low testosterone. It is whether the therapy is prescribed correctly and whether the downstream effects of treatment, mainly blood pressure and red blood cell levels, stay inside the limits the exam sets.

Is testosterone part of the DOT drug test?

No. The DOT drug test screens for five classes of drugs under federal rules: marijuana, cocaine, amphetamines, opioids, and phencyclidine (PCP). Testosterone and anabolic steroids are not on that panel (FMCSA).

This is the single most common worry among drivers who start treatment, and it is misplaced. A prescription for testosterone replacement therapy will not produce a positive result on a DOT drug screen, because the screen never looks for it.

What the DOT five-panel screens for

The federal panel is fixed by regulation under 49 CFR Part 40. The amphetamines class covers methamphetamine and MDMA, and the opioids class was expanded in 2018 to include several semi-synthetic opioids such as oxycodone and hydrocodone. Hormones are absent from every version of the panel. Any testing an employer runs beyond these five classes is separate, non-DOT testing under the employer's own authority.

Testosterone is a prescribed medication, not a street drug

Testosterone is a Schedule III controlled substance, the same category the federal government uses for anabolic steroids (DEA). That classification is why a valid prescription matters. It does not make the medication suspect on a DOT exam, but it does mean a driver should be ready to show that the testosterone is prescribed and monitored by a licensed provider.

How does a medical examiner evaluate a driver on testosterone therapy?

The examiner makes an individualized fitness decision, and a prescribed medication is allowed when the treating clinician has advised the driver that it will not affect safe driving. This standard sits in the physical qualification rules at 49 CFR 391.41, which permit use of a scheduled medication under a licensed practitioner's care.

FMCSA does not publish testosterone-specific guidance, so a certified medical examiner treats prescribed testosterone the way any other legitimate prescription is treated: as one factor in the overall picture of fitness.

The prescribed-medication standard

The regulation allows a driver to use a controlled substance when a licensed medical practitioner who is familiar with the driver's history has determined the substance will not adversely affect the driver's ability to operate a commercial vehicle. For a driver on TRT, that means the treating provider's documentation and clinical judgment are factors the examiner considers, though the examiner makes the final determination.

What documentation supports certification?

A driver who brings thorough documentation may help the exam go more smoothly and reduce the chance of a return visit. Useful documentation includes a current medication list with doses, the prescribing provider's contact information, and recent labs showing stable testosterone, hematocrit, and blood pressure. A brief letter from the treating provider stating the therapy is stable and does not impair driving addresses the exact question an examiner has to answer.

Testosterone therapy and the DOT cardiovascular standards

The place where testosterone treatment actually meets the DOT exam is cardiovascular: blood pressure and hematocrit. Both are measurable, both are affected by testosterone, and both are part of how an examiner decides fitness and certification length.

FMCSA blood pressure certification stages

Blood pressure is one of the most common reasons certification gets shortened. FMCSA ties the length of a driver's medical card to blood pressure stages (FMCSA, 2014).

Blood pressure

FMCSA stage

Certification

Below 140/90

Normal for certification

Up to 2 years

140-159 / 90-99

Stage 1

1 year

160-179 / 100-109

Stage 2

One-time 3 months; then 1 year if below 140/90

180/110 or higher

Stage 3

Disqualified until controlled; then 6-month intervals

One caution: these FMCSA stages are not the same as the American Heart Association and American College of Cardiology 2017 categories, which label Stage 1 hypertension as starting at 130/80. A driver told he has "Stage 1" in a physician's office may still meet the FMCSA cutoff. The numbers that decide the medical card are the FMCSA numbers above.

How testosterone can affect blood pressure and hematocrit

Testosterone therapy has been associated with blood pressure increases in some patients. In February 2025, the FDA added a blood-pressure warning to all testosterone product labeling and removed the older cardiovascular language from the boxed warning (FDA, 2025). For a commercial driver, that warning maps directly onto the blood pressure standard above.

Testosterone can also raise hematocrit, the share of blood made up of red blood cells, though the degree varies between individuals. Clinical guidelines set a hematocrit above 54% as the point to reduce the dose or pause therapy (Bhasin et al., 2018). In a single-center retrospective review of 247 men on testosterone, 23% went above a hematocrit of 50% and 5% went above 54% (Neidhart et al., 2025). Larger prospective studies may refine these estimates. That is why hematocrit management is a standard part of monitored care, not an afterthought.

What did the TRAVERSE trial show?

Drivers often ask whether testosterone is hard on the heart. The largest trial to date, TRAVERSE, enrolled 5,246 men with hypogonadism and cardiovascular risk and found major adverse cardiac events in 7.0% of the testosterone group versus 7.3% of the placebo group, meeting its primary non-inferiority endpoint for major adverse cardiac events (Lincoff et al., 2023). The same trial reported higher rates of atrial fibrillation (3.5% versus 2.4%), pulmonary embolism (0.9% versus 0.5%), and acute kidney injury (2.3% versus 1.5%) in the testosterone group. The authors noted that their "findings support current guidelines that testosterone should be used with caution in men who have had previous thromboembolic events." For a commercial driver, atrial fibrillation can carry its own certification questions, and any of these signals reinforce the case for regular monitoring.

What monitoring keeps a driver on TRT certifiable?

Regular monitoring helps identify when blood pressure or hematocrit moves outside acceptable ranges, allowing the provider to adjust treatment. Testosterone therapy for a diagnosed deficiency is not a set-and-forget prescription; it is a treatment that a provider tracks with regular labs and adjusts based on results, not on a fixed schedule the driver sets alone.

The diagnostic standard: symptoms plus two morning labs

Diagnosis is not based on a single low reading. The AUA defines the threshold at a total testosterone below 300 ng/dL, confirmed on two separate early-morning tests, alongside symptoms (Mulhall et al., 2018). The Endocrine Society similarly requires symptoms plus consistently low morning testosterone before treatment (Bhasin et al., 2018). An accurate diagnosis is what supports the clinical rationale for the prescription during a DOT exam. Understanding total and free testosterone helps a driver read those labs.

Ongoing monitoring that matters for drivers

Based on labs and a provider's evaluation, monitored care tracks hematocrit, blood pressure, estradiol, PSA, and testosterone levels over time. When hematocrit climbs or blood pressure rises, the provider can adjust before either one threatens the medical card. For drivers weighing family plans, testosterone can reduce fertility, an effect that is variable and not guaranteed to reverse, so fertility on testosterone therapy is worth discussing before starting. Drivers with sleep apnea, which carries its own DOT requirements, should flag it as well.

Getting evaluated as a CDL driver

Access to treatment is conditional and lawful, not automatic. A licensed clinician evaluates the driver, confirms the diagnosis with lab work, and prescribes testosterone only when it is medically appropriate. Because testosterone is a Schedule III medication, this is a real medical process, not a rubber stamp.

Telehealth has widened access. A temporary federal flexibility allows online prescribing of Schedule III medications without an initial in-person visit through December 31, 2026, though it is temporary and state law varies (DEA, 2025). A telehealth evaluation still requires labs and a clinician's review before any prescription.

For drivers who meet the diagnostic criteria, treatment and certification can coexist with proper documentation and monitoring. TRT for CDL drivers and DOT physicals is not a conflict when the treatment is prescribed for a diagnosed deficiency, documented clearly, and tracked so blood pressure and hematocrit stay inside FMCSA limits. Drivers ready to start can begin an evaluation with Marek Health and bring the results to their next exam.

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.

FAQs

Does TRT disqualify you from a DOT physical?
No, not by itself. Properly prescribed testosterone for diagnosed hypogonadism is treated like any other legitimate prescription medication. The medical examiner evaluates overall fitness and may ask for a letter from the treating provider confirming the treatment is stable and does not affect safe driving.

Is testosterone tested on a DOT drug screen? 

No. The DOT five-panel screens for marijuana, cocaine, amphetamines, opioids, and PCP. Testosterone and anabolic steroids are not on the panel, so testosterone therapy does not cause a positive DOT drug test.

What should a CDL driver on TRT bring to a DOT physical? 

Bring a current medication list, the prescribing provider's information, and recent lab work showing stable hormone levels, blood pressure, and hematocrit. A short letter from the treating clinician stating the therapy will not impair safe driving supports certification.

Can testosterone therapy raise blood pressure enough to fail a DOT physical? 

It can contribute. Testosterone can raise blood pressure and hematocrit in some patients, and a blood pressure of 180/110 or higher is disqualifying until it is controlled. Regular monitoring allows a provider to detect changes early and adjust treatment to help keep these values within the range the exam requires.

How do TRT and DOT physicals work together for CDL drivers? 

TRT for CDL drivers and DOT physicals coexist when the treatment is prescribed for a diagnosed deficiency, documented, and monitored. Testosterone is not screened on the drug test, and the exam focuses on fitness measures like blood pressure and hematocrit.

Can you get testosterone therapy through telehealth as a driver? 

Often yes, where state law allows. A licensed clinician must evaluate the driver and confirm the diagnosis with lab work before prescribing, since testosterone is a Schedule III medication. Online prescribing without an initial in-person visit is currently permitted through the end of 2026 under a temporary federal flexibility.

Does TRT affect how long a DOT medical card lasts? 

Not directly. Certification length depends on health measures like blood pressure. A driver with controlled blood pressure and stable labs can still receive up to a two-year card, while conditions that need monitoring can shorten it.

References

• DEA. Drug Scheduling.

• DEA. Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities. 2025.

• eCFR. 49 CFR 391.41, Physical qualifications for drivers.

• FDA. Class-wide labeling changes for testosterone products. 2025.

• FMCSA. Driver certification and hypertension stages. 2014.

• FMCSA. Which substances are tested.

• Front Endocrinol. 2025;15:1496906.

• J Clin Endocrinol Metab. 2018;103(5):1715-1744.

• J Urol. 2018;200:423.

• N Engl J Med. 2023;389:107-117.